TECH

Bio-Techne Corporation [TECH] Stock Forecast

Q: What is Bio-Techne Corporation stock symbol ?

Bio-Techne Corporation is a US stock, located in Minneapolis of Mn and trading under the symbol TECH

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

TECH Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

TECH has more than 3 years of cash runway (45 months)

Earnings are expected to fall -100% next year

Unstable dividend track record

EPS has been decreasing for the past 3 quarters (Quarter statements)

Profit margins (0.22%) are lower than the previous year (0.25%)

Top 10 Correlated ETFs

TECH

Top 10 Correlated Stocks

TECH

In the News

TECH Financial details

Company Rating

Strong Buy

Market Cap

10.49B

Income

224.16M

Revenue

1.14B

Book val./share

12.46

Cash/share

0.86

Dividend

0.32

Dividend %

0.44%

Employees

3.2K

Optionable

Shortable

Yes

Earnings

01 May 2024

P/E

46.14

Forward P/E

PEG

-25.75

P/S

9.95

P/B

5.7

P/C

73.28

P/FCF

52.85

Quick Ratio

2.76

Current Ratio

4.63

Debt / Equity

0.28

LT Debt / Equity

0.28

EPS (TTM)

1.42

EPS next Y

EPS next Q

EPS this Y

4.62%

EPS next Y

EPS next 5Y

EPS last 5Y

23.11%

Revenue last 5Y

9.75%

Revenue Q/Q

-1.57%

EPS Q/Q

-46.88%

SMA20

-6.94%

SMA50

-2.9%

SMA100

8.06%

Inst Own

73.53%

Inst Trans

0.78%

ROA

ROE

13%

ROC

0.11%

Gross Margin

68%

Oper. Margin

26%

Profit Margin

22%

Payout

20%

Shs Outstand

Shs Float

Target Price

52W Range

51.79-89.91

52W High

-29.19%

52W Low

+23.58%

RSI

Rel Volume

0.52

Avg Volume

1.09M

Volume

565.5K

Perf Week

-11.52%

Perf Month

-15.61%

Perf Quarter

2.85%

Perf Half Y

-8.1%

Beta

1.216

Volatility

2.32%, 3.44%

Prev Close

-1.54%

Price

63.025

Change

-3.47%

TECH Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-06-30

Metric	2019-06-30	2020-06-30	2021-06-30	2022-06-30	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	4.72	4.83	6.01	7.05	7.23
Net income per share	0.64	1.5	0.91	1.73	1.81
Operating cash flow per share	1.2	1.34	2.27	2.07	1.62
Free cash flow per share	1.03	1	1.99	1.79	1.38
Cash per share	1.1	1.77	1.49	1.57	1.3
Book value per share	7.71	9.04	10.14	10.84	12.51
Tangible book value per share	-0.97	0.89	0.72	2.21	3.56
Share holders equity per share	7.71	9.04	10.14	10.84	12.51
Interest debt per share	3.49	2.96	2.8	2.15	2.82
Market cap	7.91B	10.09B	17.45B	13.59B	12.83B
Enterprise value	8.31B	10.38B	17.67B	13.75B	13.1B
P/E ratio	82.29	44	124.26	49.97	44.98
Price to sales ratio	11.07	13.66	18.74	12.3	11.29
POCF ratio	43.53	49.16	49.54	41.8	50.44
PFCF ratio	50.61	65.73	56.67	48.49	59.36
P/B Ratio	6.78	7.3	11.1	7.99	6.52
PTB ratio	6.78	7.3	11.1	7.99	6.52
EV to sales	11.64	14.05	18.98	12.44	11.53
Enterprise value over EBITDA	56.64	65.91	74.46	34.57	32.26
EV to operating cash flow	45.75	50.56	50.17	42.27	51.51
EV to free cash flow	53.2	67.6	57.39	49.04	60.63
Earnings yield	0.01	0.02	0.01	0.02	0.02
Free cash flow yield	0.02	0.02	0.02	0.02	0.02
Debt to equity	0.43	0.31	0.27	0.19	0.23
Debt to assets	0.27	0.21	0.19	0.14	0.17
Net debt to EBITDA	2.76	1.82	0.93	0.39	0.68
Current ratio	4.05	4.88	3.35	3.44	4.84
Interest coverage	5.79	3.89	10.72	26.23	-26.66
Income quality	1.89	0.89	2.52	1.24	0.89
Dividend Yield	0.01	0	0	0	0
Payout ratio	0.5	0.21	0.35	0.18	0.18
Sales general and administrative to revenue	0.33	0.33	0.31	0.31	0.31
Research and developement to revenue	0.09	0.09	0.08	0.08	0.08
Intangibles to total assets	0.7	0.61	0.64	0.59	0.53
Capex to operating cash flow	-0.14	-0.25	-0.13	-0.14	-0.15
Capex to revenue	-0.04	-0.07	-0.05	-0.04	-0.03
Capex to depreciation	-0.33	-0.63	-0.5	-0.44	-0.36
Stock based compensation to revenue	0.05	0.04	0.05	0.04	0.03
Graham number	10.5	17.47	14.38	20.57	22.6
ROIC	0.06	0.03	0.07	0.12	0.1
Return on tangible assets	0.17	0.29	0.17	0.29	0.23
Graham Net	-2.67	-1.52	-1.89	-0.83	-1.39
Working capital	310.62M	414.25M	358.32M	429.54M	492.97M
Tangible asset value	-146.51M	136.34M	112.2M	347.39M	559.13M
Net current asset value	-306.21M	-125.48M	-181.12M	11.76M	-50.69M
Invested capital	0.43	0.31	0.27	0.19	0.23
Average receivables	128.88M	130M	133.96M	169.97M	206.51M
Average payables	67.4M	67.25M	79.62M	104.83M	95.51M
Average inventory	88.35M	97.1M	109.95M	128.94M	156.38M
Days sales outstanding	70.27	60.55	57	64.23	70.15
Days payables outstanding	108.11	90.39	117.46	118.88	76.91
Days of inventory on hand	138.18	147.36	142.91	147.55	170.76
Receivables turnover	5.19	6.03	6.4	5.68	5.2
Payables turnover	3.38	4.04	3.11	3.07	4.75
Inventory turnover	2.64	2.48	2.55	2.47	2.14
ROE	0.08	0.17	0.09	0.16	0.15
Capex per share	-0.17	-0.34	-0.29	-0.29	-0.24

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q2

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.73	1.87	1.91	1.75	1.73
Net income per share	0.32	0.45	0.48	0.32	0.17
Operating cash flow per share	0.41	0.32	0.53	0.38	0.53
Free cash flow per share	0.37	0.25	0.46	0.29	0.43
Cash per share	1.25	1	1.3	0.94	0.86
Book value per share	11.64	12.01	12.49	12.63	12.46
Tangible book value per share	2.48	2.96	3.55	2.84	2.75
Share holders equity per share	11.64	12.01	12.49	12.63	12.46
Interest debt per share	1.86	3.01	2.91	3.51	3.55
Market cap	13.01B	11.67B	12.86B	10.76B	12.16B
Enterprise value	13.14B	12.02B	13.13B	11.16B	12.58B
P/E ratio	65.06	41.55	42.58	52.77	110.64
Price to sales ratio	47.92	39.68	42.67	38.87	44.59
POCF ratio	202.12	230.95	154.17	181.26	146.24
PFCF ratio	223.3	300.9	177.19	235.07	178.09
P/B Ratio	7.12	6.18	6.54	5.39	6.19
PTB ratio	7.12	6.18	6.54	5.39	6.19
EV to sales	48.37	40.86	43.58	40.32	46.15
Enterprise value over EBITDA	138.88	112.12	108.12	132.28	192.02
EV to operating cash flow	204.05	237.81	157.46	188.01	151.36
EV to free cash flow	225.44	309.84	180.97	243.82	184.33
Earnings yield	0	0.01	0.01	0	0
Free cash flow yield	0	0	0.01	0	0.01
Debt to equity	0.16	0.25	0.23	0.28	0.28
Debt to assets	0.12	0.18	0.17	0.2	0.2
Net debt to EBITDA	1.32	3.23	2.26	4.75	6.5
Current ratio	4.4	4.04	4.84	4.63	4.37
Interest coverage	28.82	5.35K	25.53	11.42	8.78
Income quality	1.29	0.72	1.1	1.16	3.03
Dividend Yield	0	0	0	0	0
Payout ratio	0.25	0.18	0.17	0.25	0.46
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.08	0.08	0.08	0.09	0.08
Intangibles to total assets	0.61	0.55	0.53	0.56	0.56
Capex to operating cash flow	-0.09	-0.23	-0.13	-0.23	-0.18
Capex to revenue	-0.02	-0.04	-0.04	-0.05	-0.05
Capex to depreciation	-0.23	-0.44	-0.4	-0.48	-0.53
Stock based compensation to revenue	0.06	0.03	-0.01	0.04	0.05
Graham number	9.13	10.98	11.6	9.57	6.99
ROIC	0.02	0.03	0.03	0.02	0.01
Return on tangible assets	0.05	0.06	0.06	0.04	0.02
Graham Net	-0.77	-1.94	-1.39	-2.29	-2.45
Working capital	436.79M	429.83M	492.97M	463.72M	455.41M
Tangible asset value	389.87M	465.89M	559.13M	449.4M	432.87M
Net current asset value	28.89M	-139.01M	-50.69M	-166.14M	-176.55M
Invested capital	0.16	0.25	0.23	0.28	0.28
Average receivables	179.47M	200.59M	217.44M	211.52M	206.01M
Average payables	72.92M	75.15M	79.29M	78.11M	55.21M
Average inventory	155.12M	164.85M	170.55M	178.86M	183.46M
Days sales outstanding	61.23	66.22	65.25	66.48	68.49
Days payables outstanding	70.4	79.53	72.01	77.41	29.54
Days of inventory on hand	163.46	165.81	159.87	182.54	169.52
Receivables turnover	1.47	1.36	1.38	1.35	1.31
Payables turnover	1.28	1.13	1.25	1.16	3.05
Inventory turnover	0.55	0.54	0.56	0.49	0.53
ROE	0.03	0.04	0.04	0.03	0.01
Capex per share	-0.04	-0.07	-0.07	-0.09	-0.09

TECH Dividend History

TECH Frequently Asked Questions

What is Bio-Techne Corporation stock symbol ?

Bio-Techne Corporation is a US stock , located in Minneapolis of Mn and trading under the symbol TECH

What is Bio-Techne Corporation stock quote today ?

Bio-Techne Corporation stock price is $63.025 today.

Is Bio-Techne Corporation stock public?

Yes, Bio-Techne Corporation is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.09M
Market Capitalization 10.49B
Employee 3.2K
CEO Mr. Kim Kelderman
Headquarters Minneapolis,MN,US
IPO Date 1989-02-09
Website https://www.bio-techne.com

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.